News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,771 Results
Type
Article (14198)
Company Profile (282)
Press Release (252291)
Section
Business (79502)
Career Advice (153)
Deals (13224)
Drug Delivery (35)
Drug Development (50445)
Employer Resources (31)
FDA (5715)
Job Trends (5127)
News (144384)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (911)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21640)
ALS (61)
Alzheimer's disease (836)
Antibody-drug conjugate (ADC) (88)
Approvals (5733)
Artificial intelligence (112)
Autoimmune disease (13)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (20)
Breast cancer (142)
Cancer (1318)
Cardiovascular disease (112)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (308)
Cervical cancer (8)
Clinical research (40917)
Collaboration (500)
Compensation (228)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1385)
Denatured (11)
Depression (29)
Diabetes (126)
Diagnostics (1294)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (79)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (83)
Earnings (29689)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48186)
Executive appointments (410)
FDA (6347)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (471)
Gene editing (90)
Generative AI (9)
Gene therapy (234)
GLP-1 (358)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6590)
Huntington's disease (21)
IgA nephropathy (22)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (58)
Interviews (17)
IPO (7263)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (203)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (187)
Lymphoma (84)
Machine learning (1)
Management (7)
Manufacturing (116)
MASH (49)
Medical device (2589)
Medtech (2590)
Mergers & acquisitions (6258)
Metabolic disorders (366)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (61)
Neuropsychiatric disorders (23)
Neuroscience (1214)
NextGen: Class of 2025 (2017)
Non-profit (852)
Northern California (1575)
Now hiring (21)
Obesity (186)
Opinion (100)
Ovarian cancer (60)
Pain (41)
Pancreatic cancer (51)
Parkinson's disease (111)
Partnered (8)
Patents (112)
Patient recruitment (68)
Peanut (35)
People (25521)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14445)
Phase II (19036)
Phase III (12040)
Pipeline (744)
Podcasts (47)
Policy (38)
Postmarket research (852)
Preclinical (6067)
Press Release (30)
Prostate cancer (55)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (277)
Real estate (1415)
Recruiting (12)
Regulatory (8576)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (4)
RSV (10)
Schizophrenia (56)
Series A (92)
Series B (60)
Service/supplier (1)
Sickle cell disease (39)
Southern California (1394)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
Tariffs (3)
The Weekly (35)
United States (12279)
Vaccines (205)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (65)
Last 7 days (405)
Last 30 days (1603)
Last 365 days (19965)
2025 (4949)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17226)
Australia (2921)
California (3571)
Canada (1059)
China (326)
Colorado (138)
Connecticut (143)
Delaware (88)
Europe (37050)
Florida (423)
Georgia (110)
Idaho (16)
Illinois (214)
India (9)
Indiana (87)
Iowa (1)
Japan (71)
Kansas (60)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (446)
Massachusetts (2820)
Michigan (69)
Minnesota (138)
Mississippi (1)
Missouri (23)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (893)
New Mexico (12)
New York (968)
North Carolina (525)
North Dakota (4)
Northern California (1575)
Ohio (108)
Oklahoma (9)
Oregon (21)
Pennsylvania (680)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1394)
Tennessee (25)
Texas (412)
Utah (48)
Virginia (70)
Washington D.C. (28)
Washington State (324)
Wisconsin (13)
266,771 Results for "rubryc therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
RubrYc Therapeutics Announces Series A2 Preferred Equity Financing, Collaboration, and RTX-003 License with iBio, Inc.
RubrYc Therapeutics, Inc. (“RubrYc”) and iBio, Inc. (“iBio”, NYSEA: IBIO) announced today the closing of RubrYc’s Series A2 Preferred Financing, and concomitant License and Collaboration Agreements directed towards the research, development, and commercialization of epitope-targeted antibody therapeutics.
August 25, 2021
·
4 min read
Business
RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an undisclosed oncology target.
April 13, 2021
·
2 min read
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System
November 10, 2022
·
7 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Biotech Bay
RubrYc Therapeutics To Present at AACR Virtual Conference
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, today announced the presentation of discovery and pre-clinical data from their lead program RTX-003, a CD25 targeted monoclonal antibody for selective depletion of regulatory T cells (Tregs) in the tumor microenvironment (TME). A poster ti
June 23, 2020
·
3 min read
Business
RubrYc Therapeutics Announces formation of its Scientific Advisory Board
RubrYc’s SAB will leverage synergistic expertise in structural and computational biology, translational sciences, and market and clinical insights.
December 4, 2019
·
4 min read
Layoffs
Repare Therapeutics to Cut Staff Again, This Time by 75%
The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.
February 25, 2025
·
2 min read
·
Angela Gabriel
Drug Development
RubrYc Therapeutics Appoints Ramesh Baliga, Ph.D. as Chief Science Officer
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, today announced the appointment of Ramesh Baliga, Ph.D., as the Company’s Chief Science Officer.
March 18, 2020
·
3 min read
Press Releases
CRISPR Therapeutics Announces Transition of Chief Operating Officer
March 26, 2025
·
1 min read
Business
RubrYc Therapeutics Appoints Rakesh Verma, Ph.D. as SVP Discovery & Development
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, announced the appointment of Rakesh Verma, Ph.D., as the Company’s Senior Vice President, Discovery & Development.
November 12, 2019
·
3 min read
1 of 26,678
Next